Lyell Immunopharma (LYEL) Operating Income (2020 - 2026)

Lyell Immunopharma's Operating Income history runs 7 years deep, the most recent figure standing at -$44.3 million for Q1 2026.

• In Q1 2026, Operating Income rose 22.85% year-over-year to -$44.3 million; the TTM figure through Mar 2026 stood at -$256.3 million (up 28.91% YoY), while the FY2025 annual figure was -$269.4 million, up 24.91% from the prior year.
• Operating Income came in at -$44.3 million for Q1 2026 at Lyell Immunopharma, up from -$127.6 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$14.8 million in Q4 2022 to a low of -$201.1 million in Q4 2024.
• A 5-year average of -$65.1 million and a median of -$57.4 million in 2025 frame the typical range for Operating Income.
• Across the five-year window, Operating Income surged 68.9% in 2022 and tumbled 302.52% in 2023, its largest moves.
• Lyell Immunopharma's Operating Income stood at -$14.8 million in 2022, then sank by 302.52% to -$59.5 million in 2023, then tumbled by 238.02% to -$201.1 million in 2024, then surged by 36.54% to -$127.6 million in 2025, then jumped by 65.32% to -$44.3 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$44.3 million, -$127.6 million, and -$37.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison